For the Inventor, By the Inventor

Enter assignee name

Obi Pharma Inc.

USPTO Granted Patents = 25

CIPO Patents = 4

EPO Patents = 9

Trademarks = 2

Forward Citations = 17

Loading Chart...

Loading Chart...

45 inventors (with patents filed for the assignee):

Cheng-Der Tony Yu (15 out of 16 patents)

I-Ju Chen (14 out of 16 patents)

Jiann-Shiun Lai (10 out of 10 patents)

4. Cheng-Chi Wang (6 out of 10 patents)

5. Yi-Chien Tsai (5 out of 5 patents)

6. Jian-Xin Duan (5 out of 18 patents)

7. Yeyu Cao (5 out of 7 patents)

8. Xiaohong Cai (5 out of 7 patents)

9. Jing Yuan Ma (5 out of 6 patents)

10. Yih-Huang Hsieh (5 out of 5 patents)

11. Hailong Jiao (5 out of 12 patents)

12. Mark D Matteucci (5 out of 65 patents)

13. Yu-Hsin Lin (3 out of 68 patents)

14. Nan-Hsuan Wang (3 out of 3 patents)

15. Chiu-Chun Lin (3 out of 3 patents)

25 patents: Sort by Forward Citations

1. 12234266 - CRM197 protein expression (2025-02-25),

2. 12221461 - Saponin adjuvant and evaluation method thereof (2025-02-11),

3. 12090212 - Conjugated biological molecules, pharmaceutical compositions and methods (2024-09-17),

4. 12053514 - Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment (2024-08-06),

5. 11833223 - Antibodies, pharmaceutical compositions and methods (2023-12-05),

6. 11773118 - Methods of making high enantioselective secondary alcohols (2023-10-03),

7. 11752204 - Vaccines with higher carbohydrate antigen density and novel saponin adjuvant (2023-09-12),

8. 11643456 - Human antibodies, pharmaceutical compositions and methods (2023-05-09),

9. 11642400 - Immunogenic/therapeutic glycan compositions and uses thereof (2023-05-09),

10. 11583577 - Cancer immunotherapy by immune activation or immune modulation via Globo series antigens (2023-02-21),

11. 11535585 - Nitrobenzyl derivatives of anti-cancer agents (2022-12-27),

12. 11236154 - Carbohydrate antibodies, pharmaceutical compositions and uses thereof (2022-02-01),

13. 11203645 - Glycosynthase variants for glycoprotein engineering and methods of use (2021-12-21),

14. 11041017 - Antibodies, pharmaceutical compositions and methods (2021-06-22),

15. 11000601 - Conjugated biological molecules, pharmaceutical compositions and methods (2021-05-11),

OBI Pharma Inc. is a Taiwan-based biopharmaceutical company dedicated to developing novel oncology therapeutics. With a focus on immuno-oncology and tumor-targeting therapies, OBI Pharma aims to improve the lives of cancer patients worldwide. They harness the power of innovative science and technology to create breakthrough treatments that combat various types of cancer. With a strong commitment to research and development, OBI Pharma strives to make significant advancements in the field of oncology and bring hope to those affected by cancer.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

25 Patents

#227 in Taipei

#667 in Taiwan

#24,954 in the World

Obi Pharma Inc.

Forward Citations = 17

45 inventors:

Cheng-Der Tony Yu (15 out of 16 patents)

I-Ju Chen (14 out of 16 patents)

Jiann-Shiun Lai (10 out of 10 patents)

4. Cheng-Chi Wang (6 out of 10 patents)

5. Yi-Chien Tsai (5 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…